Odyssey Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ODTX in the last 30 days.
See all $ODTX insider activity →Odyssey Therapeutics (ODTX) reported Q2 2026 results with $433.1M cash, enough for operations into 2028. The company is advancing its lead drug OD-001, with Phase 2a data expected in October and two new trials planned. Net loss widened to $52.8M due to increased R&D spending. The company has no product revenue yet.
Pro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.
Odyssey Therapeutics (ODTX) debuted on Nasdaq at $20, raising $279M via an upsized offering. Shares initially climbed 13% but later fell 10% to $16. The company also raised $25M in a private placement, totaling $304M. Proceeds will fund drug development, including OD-001 for ulcerative colitis and Crohn's disease. The company reported net losses of $148.6M in 2025 and $129.3M in 2024, with $175.7M in cash as of March 2026.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ODTX (Odyssey Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ODTX coverage spans earnings, financial news and ipo.
The cash runway and trial expansion may support upside, but widening losses and delayed data keep risk elevated.
Phase‑2b initiation may boost investor confidence despite larger loss.
Large capital raise and volatile debut create immediate trading opportunity.
Coverage may boost interest in the biotech's pipeline.
The deal can enhance pipeline development prospects, but near-term impact depends on milestone funding and target selection.
AlphAI scores every news story that mentions ODTX with an AI model for sentiment and relevance, and aggregates insider trades from Odyssey Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Odyssey Therapeutics (ODTX) reported Q2 2026 results with $433.1M cash, enough for operations into 2028. The company is advancing its lead drug OD-001, with Phase 2a data expected in October and two new trials planned. Net loss widened to $52.8M due to increased R&D spending. The company has no product revenue yet.
2 min readPro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.
2 min readOdyssey Therapeutics (ODTX) debuted on Nasdaq at $20, raising $279M via an upsized offering. Shares initially climbed 13% but later fell 10% to $16. The company also raised $25M in a private placement, totaling $304M. Proceeds will fund drug development, including OD-001 for ulcerative colitis and Crohn's disease. The company reported net losses of $148.6M in 2025 and $129.3M in 2024, with $175.7M in cash as of March 2026.
2 min readHC Wainwright initiated coverage on Ascendis Pharma (ASND) with a Buy rating and $345 price target. Truist Securities initiated DigitalOcean (DOCN) with a Buy rating and $175 target. HC Wainwright also initiated Odyssey Therapeutics (ODTX) with a Buy rating and $44 target.
1 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readOdyssey Therapeutics (ODTX) reported a wider Q2 2026 net loss of $52.8M, up from $41.2M a year earlier, driven by higher external R&D spending. Q2 R&D was $36.2M versus $30.2M in 2025. Cash and marketable securities totaled $433.1M, expected to fund operations into 2028. Pipeline updates include OD-001 Phase 2a expansion and further trials in 2026.
4 min readA dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
4 min readEvotec SE (NASDAQ: EVO) said it entered an R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to use Evotec’s AI-enabled discovery platform and screening capabilities to discover and validate small-molecule drug candidates for autoimmune and inflammatory diseases. Evotec will deliver validated hit series across multiple targets and may receive milestone payments; no financial terms were disclosed.
2 min readOdyssey Therapeutics, Inc. (ODTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedoliz
2 min readOdyssey Therapeutics, Inc. (ODTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001882782 0001882782 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
2 min read
